Dynavax Technologies (DVAX)

$15.49 -0.02 (-0.13%)
Market Cap 1.82B
Revenue (ttm) 277.25M
Net Income (ttm) 27.31M
EPS (ttm) N/A
PE Ratio 53.38
Forward PE 24.77
Profit Margin 9.85%
Debt to Equity Ratio 0.08
Volume 3,634,600
Avg Vol 3,352,852
Day's Range N/A - N/A
Shares Out 117.43M
Stochastic %K 23%
Beta 0.97
Analysts Sell
Price Target $21.00

Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States and internationally. The company offers HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults aged 18 years and older; and CpG 1018, the adjuvant used in HEPLISAV-B. It also develops rF1V, a plague vaccine candidate in Phase 2 clinical trial; and Z-1018, an investigational vaccin...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 510 848 5100
Fax: 510 848 1327
Address:
2100 Powell Street, Suite 720, EmeryVille, United States
WALTERPAYTON34
WALTERPAYTON34 Feb. 6 at 2:44 PM
$DVAX $VXRT
0 · Reply
WALTERPAYTON34
WALTERPAYTON34 Feb. 6 at 2:44 PM
$DVAX $VXRT
0 · Reply
freeze19
freeze19 Feb. 6 at 1:56 PM
$DVAX So, I got a phone call last evening. From a firm hired by Sanofi. They were asking me if I had tendered my shares yet, and if not, strongly encouraged me to do so. This seemed highly unusual as I've had shares of companies that had been sold before. I did nothing, and the shares eventually got converted to money. She said that they need a certain percentage of shares tendered for the sale to go through. I asked why she was calling me, is the company worried that not enough shares would be tendered? She was just a marketing company hired to call, she had no idea. And her little kids interrupted the call twice. So, if I don't tender my shares, what happens? I assume if enough shared are tendered my shares would be sold by default anyway
1 · Reply
user429472
user429472 Feb. 5 at 4:27 PM
$DVAX I just wanted to go on record to say that I believe that this is a bad deal. I believe the company is worth way more than what management/board agreed to. I don't like how everything went with DeepTrack. I do not like how debt has been handled in the past. I do not like how much the company diluted shareholders over the years and then left the amount of cash on hand to be taken over in the deal. I believe cpg-1018 is much more valuable than what it is being acquired especially combined with the projected market share growth of Heplisav-b. I believe the pipeline's potential, the growth of Heplisav-b, the possible partnership deals in the works, a greater expansion into Europe, and the other deals (TLSI (SD-101), VXRT) make this much more valuable. Regarding the deal, I did not like what I read regarding the possible scenario of Sanofi gaining a majority share over those who did not tender. Unfortunately, I am a tiny fish who after about 10 years of holding is reluctantly out.GLTA
1 · Reply
DaPod
DaPod Feb. 5 at 1:39 PM
$DVAX Has anyone actually received the tender offer by mail or email so they could vote on the merger?? I cannot find that I have, yet they talk of closing Feb 9.
1 · Reply
WALTERPAYTON34
WALTERPAYTON34 Feb. 5 at 3:07 AM
$DVAX $VXRT As of now, there is no specific mention of Samba Merger Sub's direct involvement in Vaxart beyond their association with Dynavax. If you need more details about the specifics of either company's operations regarding vaccines or further inquiries about their partnerships,
0 · Reply
WALTERPAYTON34
WALTERPAYTON34 Feb. 5 at 2:58 AM
$DVAX $VXRT Sanofi’s Subsidiaries Sanofi Pasteur Genzyme Shantha Biotechnics Chattem Ablynx Bioverativ Opella
0 · Reply
WALTERPAYTON34
WALTERPAYTON34 Feb. 5 at 2:53 AM
$DVAX $VXRT In February 2022, Sanofi's new corporate brand was unveiled and former entity "Sanofi Genzyme" was integrated into Sanofi.[3][4] Genzyme Sanofi Genzyme headquarters in Cambridge, Massachusetts in 2007
0 · Reply
WALTERPAYTON34
WALTERPAYTON34 Feb. 5 at 2:48 AM
$DVAX $VXRT Yes, Samba Merger Sub, Inc. is an indirect wholly owned subsidiary of Sanofi. It has been established in the context of Sanofi's acquisition of Dynavax Technologies Corporation, where Samba Merger Sub is facilitating the tender offer to purchase Dynavax's outstanding shares. This merger process offers significant financial opportunities, reflecting a total equity value of around $2.2 billion for Dynavax, with an offer price of $15.50 per share. This indicates that Sanofi does indeed have ownership over Samba Merger Sub, which is directly involved in this acquisition.
0 · Reply
WALTERPAYTON34
WALTERPAYTON34 Feb. 5 at 2:45 AM
$DVAX $VXRT What are the financial implications of the Samba Merger Sub for investors? Samba Merger Sub, a subsidiary of Sanofi, is offering to acquire all outstanding shares of Dynavax for $15.50 per share in cash, which represents a 39% premium over Dynavax's closing price prior to the announcement. This acquisition could provide investors with a significant return on their investment if they choose to sell their shares during the tender offer.
0 · Reply
Latest News on DVAX
Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

Feb 4, 2026, 6:15 PM EST - 1 day ago

Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600

ADT ARWR CIEN DAY OSW

Shares of Dynamax Are Up Nearly 40% Today. Here's Why The Stock Is Flying

Dec 24, 2025, 11:05 AM EST - 6 weeks ago

Shares of Dynamax Are Up Nearly 40% Today. Here's Why The Stock Is Flying

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion.

Dec 24, 2025, 7:59 AM EST - 6 weeks ago

This Biotech Stock Is Soaring. Sanofi Is Buying It for $2.2 Billion.

SNY

Sanofi to acquire Dynavax for $2.2B, sending shares higher by 37%

Dec 24, 2025, 6:49 AM EST - 6 weeks ago

Sanofi to acquire Dynavax for $2.2B, sending shares higher by 37%

Sanofi to acquire US biotech Dynavax for $2.2 billion

Dec 24, 2025, 3:08 AM EST - 6 weeks ago

Sanofi to acquire US biotech Dynavax for $2.2 billion

SNY

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal

Dec 24, 2025, 1:49 AM EST - 6 weeks ago

Sanofi to Buy Vaccine Maker Dynavax in $2.2 Billion Deal

SNY

Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline

Dec 24, 2025, 1:23 AM EST - 6 weeks ago

Sanofi to Acquire Dynavax, Adding a Marketed Adult Hepatitis B Vaccine and Phase 1/2 Shingles Candidate to the Pipeline

Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline

Dec 24, 2025, 1:15 AM EST - 6 weeks ago

Press Release: Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline

SNY

Dynavax to Participate at the 8th Annual Evercore Healthcare Conference

Nov 19, 2025, 4:01 PM EST - 2 months ago

Dynavax to Participate at the 8th Annual Evercore Healthcare Conference

Dynavax Technologies Corporation (DVAX) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 10:31 PM EST - 3 months ago

Dynavax Technologies Corporation (DVAX) Q3 2025 Earnings Call Transcript

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

Nov 5, 2025, 4:01 PM EST - 3 months ago

Dynavax Reports Third Quarter 2025 Financial Results and Announces New $100 Million Share Repurchase Program

VXRT

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

Nov 5, 2025, 4:00 PM EST - 3 months ago

Dynavax Enters Exclusive License Agreement for Vaxart's Novel Oral COVID-19 Vaccine Program

VXRT

Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025

Oct 22, 2025, 4:01 PM EDT - 3 months ago

Dynavax to Report Third Quarter 2025 Financial Results and Host Conference Call on November 5, 2025

Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial

Oct 21, 2025, 4:01 PM EDT - 3 months ago

Dynavax Presents Positive Topline Data from Part 1 of Phase 1/2 Trial for Shingles Vaccine Candidate at IDWeek 2025 and Announces Initiation of Part 2 of Trial

3 Of My Favorite Biotech Stocks Under $10

Sep 29, 2025, 1:15 PM EDT - 4 months ago

3 Of My Favorite Biotech Stocks Under $10

FOLD MRNA NUVB PFE

Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference

Aug 27, 2025, 4:05 PM EDT - 5 months ago

Dynavax to Participate in the 2025 Wells Fargo Healthcare Conference

Dynavax's shingles vaccine shows similar immune response to GSK's shot in study

Aug 21, 2025, 8:22 AM EDT - 6 months ago

Dynavax's shingles vaccine shows similar immune response to GSK's shot in study

GSK

Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile

Aug 21, 2025, 8:00 AM EDT - 6 months ago

Dynavax Announces Positive Topline Phase 1/2 Results Supporting Potential Best-in-Class Shingles Vaccine Profile

Dynavax Technologies: A Dip To Accumulate

Aug 11, 2025, 8:41 AM EDT - 6 months ago

Dynavax Technologies: A Dip To Accumulate

Dynavax Technologies Corporation (DVAX) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 10:51 PM EDT - 6 months ago

Dynavax Technologies Corporation (DVAX) Q2 2025 Earnings Call Transcript

Dynavax Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:00 PM EDT - 6 months ago

Dynavax Reports Second Quarter 2025 Financial Results

Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Jul 29, 2025, 4:02 PM EDT - 6 months ago

Dynavax to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Dynavax elects all four of its nominees after Deep Track proxy fight

Jun 11, 2025, 12:14 PM EDT - 8 months ago

Dynavax elects all four of its nominees after Deep Track proxy fight

Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting

Jun 11, 2025, 11:01 AM EDT - 8 months ago

Dynavax Stockholders Elect All Dynavax Director Nominees at 2025 Annual Meeting

Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom

Jun 9, 2025, 8:30 AM EDT - 8 months ago

Deep Track Capital Sends Letter to Dynavax Technologies Shareholders Offering Final Perspectives on Why Change is Needed in the Boardroom

Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting

Jun 9, 2025, 7:30 AM EDT - 8 months ago

Dynavax Urges Stockholders to Support Its Director Nominees at June 11 Annual Meeting

Dynavax Comments on Glass Lewis Recommendation

Jun 4, 2025, 4:59 PM EDT - 8 months ago

Dynavax Comments on Glass Lewis Recommendation

Glass Lewis Recommends Shareholders Support Deep Track's Case for Board Change at Dynavax Technologies

Jun 4, 2025, 9:27 AM EDT - 8 months ago

Glass Lewis Recommends Shareholders Support Deep Track's Case for Board Change at Dynavax Technologies

Dynavax to Present at William Blair's 45th Annual Growth Stock Conference

May 28, 2025, 4:10 PM EDT - 9 months ago

Dynavax to Present at William Blair's 45th Annual Growth Stock Conference

Deep Track Capital Comments on ISS Recommendation

May 23, 2025, 6:12 PM EDT - 9 months ago

Deep Track Capital Comments on ISS Recommendation

ISS backs Dynavax directors in board fight with Deep Track Capital

May 23, 2025, 1:54 PM EDT - 9 months ago

ISS backs Dynavax directors in board fight with Deep Track Capital

Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees

May 23, 2025, 1:44 PM EDT - 9 months ago

Leading Independent Proxy Advisory Firm ISS Recommends Stockholders Vote "FOR" All Four of Dynavax's Highly Qualified Director Nominees

Dynavax Technologies: Hepatitis-B Vaccine Specialist Looking Good

May 21, 2025, 11:48 PM EDT - 9 months ago

Dynavax Technologies: Hepatitis-B Vaccine Specialist Looking Good

Deep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual Meeting

May 15, 2025, 4:00 PM EDT - 9 months ago

Deep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual Meeting

Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value

May 12, 2025, 7:30 AM EDT - 9 months ago

Dynavax Files Investor Presentation Highlighting Superior Strategy and Board That is Delivering Strong Financial Results and Significant Long-Term Value

Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum

May 7, 2025, 4:45 PM EDT - 9 months ago

Dynavax Issues Statement and Mails Letter to Stockholders Emphasizing Record Financial Results and Continued Momentum

Dynavax Technologies Corporation (DVAX) Q1 2025 Earnings Call Transcript

May 6, 2025, 7:34 PM EDT - 9 months ago

Dynavax Technologies Corporation (DVAX) Q1 2025 Earnings Call Transcript

Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs

May 6, 2025, 4:01 PM EDT - 9 months ago

Dynavax Reports First Quarter 2025 Financial Results and Announces New Pipeline Programs

Deep Track Capital Releases Investor Presentation on Dynavax Technologies

May 6, 2025, 8:00 AM EDT - 9 months ago

Deep Track Capital Releases Investor Presentation on Dynavax Technologies

Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits

May 1, 2025, 8:00 AM EDT - 10 months ago

Dynavax Announces Nationwide Harris Poll Survey Results Finding Americans Underestimate the Serious Consequences of Hepatitis B and Vaccine Protection Benefits

Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy

Apr 29, 2025, 7:30 AM EDT - 10 months ago

Dynavax Highlights Superior Board Leadership Overseeing Long-Term Value Creation Strategy

Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

Apr 22, 2025, 4:00 PM EDT - 10 months ago

Dynavax to Report First Quarter 2025 Financial Results and Host Conference Call on May 6, 2025

Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders

Apr 21, 2025, 4:05 PM EDT - 10 months ago

Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders

Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders

Apr 17, 2025, 7:15 AM EDT - 10 months ago

Dynavax Files Definitive Proxy Statement and Sends Letter to Stockholders

Deep Track Capital Comments on Dynavax Technologies' Rejection of Most Recent Settlement Offer

Apr 16, 2025, 8:00 AM EDT - 10 months ago

Deep Track Capital Comments on Dynavax Technologies' Rejection of Most Recent Settlement Offer

WALTERPAYTON34
WALTERPAYTON34 Feb. 6 at 2:44 PM
$DVAX $VXRT
0 · Reply
WALTERPAYTON34
WALTERPAYTON34 Feb. 6 at 2:44 PM
$DVAX $VXRT
0 · Reply
freeze19
freeze19 Feb. 6 at 1:56 PM
$DVAX So, I got a phone call last evening. From a firm hired by Sanofi. They were asking me if I had tendered my shares yet, and if not, strongly encouraged me to do so. This seemed highly unusual as I've had shares of companies that had been sold before. I did nothing, and the shares eventually got converted to money. She said that they need a certain percentage of shares tendered for the sale to go through. I asked why she was calling me, is the company worried that not enough shares would be tendered? She was just a marketing company hired to call, she had no idea. And her little kids interrupted the call twice. So, if I don't tender my shares, what happens? I assume if enough shared are tendered my shares would be sold by default anyway
1 · Reply
user429472
user429472 Feb. 5 at 4:27 PM
$DVAX I just wanted to go on record to say that I believe that this is a bad deal. I believe the company is worth way more than what management/board agreed to. I don't like how everything went with DeepTrack. I do not like how debt has been handled in the past. I do not like how much the company diluted shareholders over the years and then left the amount of cash on hand to be taken over in the deal. I believe cpg-1018 is much more valuable than what it is being acquired especially combined with the projected market share growth of Heplisav-b. I believe the pipeline's potential, the growth of Heplisav-b, the possible partnership deals in the works, a greater expansion into Europe, and the other deals (TLSI (SD-101), VXRT) make this much more valuable. Regarding the deal, I did not like what I read regarding the possible scenario of Sanofi gaining a majority share over those who did not tender. Unfortunately, I am a tiny fish who after about 10 years of holding is reluctantly out.GLTA
1 · Reply
DaPod
DaPod Feb. 5 at 1:39 PM
$DVAX Has anyone actually received the tender offer by mail or email so they could vote on the merger?? I cannot find that I have, yet they talk of closing Feb 9.
1 · Reply
WALTERPAYTON34
WALTERPAYTON34 Feb. 5 at 3:07 AM
$DVAX $VXRT As of now, there is no specific mention of Samba Merger Sub's direct involvement in Vaxart beyond their association with Dynavax. If you need more details about the specifics of either company's operations regarding vaccines or further inquiries about their partnerships,
0 · Reply
WALTERPAYTON34
WALTERPAYTON34 Feb. 5 at 2:58 AM
$DVAX $VXRT Sanofi’s Subsidiaries Sanofi Pasteur Genzyme Shantha Biotechnics Chattem Ablynx Bioverativ Opella
0 · Reply
WALTERPAYTON34
WALTERPAYTON34 Feb. 5 at 2:53 AM
$DVAX $VXRT In February 2022, Sanofi's new corporate brand was unveiled and former entity "Sanofi Genzyme" was integrated into Sanofi.[3][4] Genzyme Sanofi Genzyme headquarters in Cambridge, Massachusetts in 2007
0 · Reply
WALTERPAYTON34
WALTERPAYTON34 Feb. 5 at 2:48 AM
$DVAX $VXRT Yes, Samba Merger Sub, Inc. is an indirect wholly owned subsidiary of Sanofi. It has been established in the context of Sanofi's acquisition of Dynavax Technologies Corporation, where Samba Merger Sub is facilitating the tender offer to purchase Dynavax's outstanding shares. This merger process offers significant financial opportunities, reflecting a total equity value of around $2.2 billion for Dynavax, with an offer price of $15.50 per share. This indicates that Sanofi does indeed have ownership over Samba Merger Sub, which is directly involved in this acquisition.
0 · Reply
WALTERPAYTON34
WALTERPAYTON34 Feb. 5 at 2:45 AM
$DVAX $VXRT What are the financial implications of the Samba Merger Sub for investors? Samba Merger Sub, a subsidiary of Sanofi, is offering to acquire all outstanding shares of Dynavax for $15.50 per share in cash, which represents a 39% premium over Dynavax's closing price prior to the announcement. This acquisition could provide investors with a significant return on their investment if they choose to sell their shares during the tender offer.
0 · Reply
WALTERPAYTON34
WALTERPAYTON34 Feb. 5 at 2:44 AM
$DVAX $VXRT Samba Financial Group Overview Samba Financial Group, formerly known as The Saudi American Bank, was a major banking institution in Saudi Arabia. It was established in 1980 and operated until its merger with the National Commercial Bank (NCB) on April 1, 2021, forming the Saudi National Bank. Key Details of the Merger Merger Date: April 1, 2021 New Entity: Saudi National Bank Branches: The combined institution operates 66 branches in Saudi Arabia. Shareholder Exchange: Samba shareholders received between 0.736 and 0.787 shares of NCB for each Samba share they held.
0 · Reply
WALTERPAYTON34
WALTERPAYTON34 Feb. 5 at 2:43 AM
$DVAX $VXRT Samba Merger Sub refers to a subsidiary created for the purpose of facilitating a merger, specifically in the context of Samba Financial Group's merger with the National Commercial Bank (NCB) to form the Saudi National Bank. This subsidiary would handle the transaction details and integration of the two banking entities.
0 · Reply
WALTERPAYTON34
WALTERPAYTON34 Feb. 5 at 2:41 AM
$DVAX $VXRT
0 · Reply
Stanplain
Stanplain Feb. 5 at 2:40 AM
$DVAX what happens if nobody tenders? Deal falls apart? Better offer?
0 · Reply
WALTERPAYTON34
WALTERPAYTON34 Feb. 5 at 2:35 AM
$DVAX $VXRT https://www.bizapedia.com/de/samba-merger-sub-inc.html
0 · Reply
WALTERPAYTON34
WALTERPAYTON34 Feb. 5 at 2:18 AM
$DVAX $VXRT
0 · Reply
NLPforTrading
NLPforTrading Feb. 4 at 1:41 PM
$DVAX is a biotech with an approved adjuvant used in hepatitis B and pandemic influenza vaccines; its revenue is dependent on partnership milestones and royalties rather than direct sales.
1 · Reply
pauliedeee
pauliedeee Feb. 3 at 10:40 PM
$VXRT $DVAX $SNY Coming soon to a theater near you!
0 · Reply
TwongStocks
TwongStocks Feb. 3 at 9:10 PM
$DVAX Equity Corporate Actions Alert #2026 - 67 Information Regarding the Tender Offer of Dynavax Technologies Corporation (DVAX) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-67 The tender offer by Samba Merger Sub, Inc. to acquire all of the outstanding common stock of Dynavax Technologies Corporation (DVAX) is scheduled to expire one minute after 11:59 p.m. ET, on February 9, 2026, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on February 10, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on February 9, 2026. If the merger closes as planned, the stock will remain halted on the day of closing (February 10) and will be suspended effective February 11, 2026. DVAX shareholders will receive $15.50 per share at closing.
0 · Reply
Dilly_Due
Dilly_Due Feb. 3 at 2:39 PM
$VXRT $DVAX $SNY $MRK Wouldn't be the first time.... Think $30+/share is unattainable? From chat GPT. Just my humble opinion. Do your own DD.
0 · Reply
Vax87
Vax87 Feb. 2 at 9:44 PM
$VXRT If it is true, that $SNY was in talks for at least 2 years with $DVAX , then, $SNY obviously prodded them to follow through with the Vaxart deal. If I told you 6 months ago that Sanofi was going to buy the rights to our Covid vaccine with the same terms that we got through the Dvax deal, what would the reaction have been? Well, everyone would have gone crazy if it truly happened, and, we would have all expected the share price to have gone 2+ instantly. Well, the reality is, it did happen. Why is the share price still meandering here? Does anyone think that the share price has yet to react to this reality, as unbelievable as that sounds?
2 · Reply
KWalzz
KWalzz Feb. 2 at 1:08 PM
$DVAX and another "unimportant" amendment to SC14D9. it is only about CEO Spencer listed 11 million while it was 6 million (compensation for GS). I mean who needs to be correct in financial matters or so? LOL
0 · Reply